Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned a consensus rating of “Moderate Buy” from the twenty-five research firms that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $793.8095.

REGN has been the topic of a number of research reports. Citigroup raised their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Evercore raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd.

Regeneron Pharmaceuticals Stock Up 2.5%

Shares of REGN opened at $803.17 on Tuesday. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company’s fifty day moving average is $764.16 and its two-hundred day moving average is $668.40. The firm has a market cap of $84.91 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $12.07 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,636 shares of company stock worth $2,862,920 over the last quarter. 7.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC raised its stake in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares during the last quarter. MCF Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares during the last quarter. CYBER HORNET ETFs LLC raised its position in shares of Regeneron Pharmaceuticals by 6.0% during the 4th quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 17 shares in the last quarter. Finally, Meyer Handelman Co. lifted its stake in Regeneron Pharmaceuticals by 0.6% during the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after purchasing an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.